← Leaderboards
Michael W Deininger
Versiti Blood Health, Inc.
$12,562,286
Attributed
$13,851,323
Total exposure
10
Grants
9
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.7M · FY2005–25$2M$1.5M$1M$500K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$13,851,323 · 10
By mechanism
R01$10,287,790 · 5
P01$1,556,520 · 1
S10$1,040,397 · 2
R21$966,616 · 2
Top collaborators
- Thomas J. O'Hare5 shared
Others in their field
Top investigators on “Cells”
- Lawrence Corey · Fred Hutchinson Cancer Center$536,344,731
- Barton F Haynes · Duke University$457,457,619
- David Heimbrook · Leidos Biomedical Research, Inc.$454,789,509
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$299,104,942
- Dennis R. Burton · Scripps Research Institute$278,781,854
- Mary M Horowitz · Medical College Of Wisconsin$237,383,608
Research focus
CellsResponseLeukemiaExhibitsPharmaceutical PreparationsResistanceSamplingMutantIn VivoDependenceApoptosisTargeted TreatmentInhibitor/AntagonistSignal TransductionAcute Myelocytic LeukemiaBiologyPhosphotransferasesRelapseChronic Myeloid LeukemiaCell LineIn VitroLeukemic CellKnock-DownBase
Grant awards (38)
High parameter fluorescence activated cell sorter$679,925
S10 · FY2025 · OD · contact PI
The function of MS4A3 in normal and malignant hematopoiesis$473,053
R01 · FY2025 · CA · contact PI
Strategies to target BCR-ABL1 compound mutants in CML and Ph+ ALL$377,438
R01 · FY2025 · CA · contact PI
The function of MS4A3 in normal and malignant hematopoiesis$592,404
R01 · FY2024 · CA · contact PI
Strategies to target BCR-ABL1 compound mutants in CML and Ph+ ALL$358,566
R01 · FY2024 · CA · contact PI
Targeting the Metabolic Regulator SIRT5 in Acute Myeloid Leukemia$358,565
R01 · FY2024 · CA · contact PI
Targeting the Metabolic Regulator SIRT5 in Acute Myeloid Leukemia$352,688
R01 · FY2024 · CA · contact PI
The function of MS4A3 in normal and malignant hematopoiesis$466,620
R01 · FY2023 · CA · contact PI
Targeting the Metabolic Regulator SIRT5 in Acute Myeloid Leukemia$371,250
R01 · FY2023 · CA · contact PI
Targeting the Metabolic Regulator SIRT5 in Acute Myeloid Leukemia$369,889
R01 · FY2023 · CA · contact PI
Strategies to target BCR-ABL1 compound mutants in CML and Ph+ ALL$369,889
R01 · FY2023 · CA · contact PI
Targeting the Metabolic Regulator SIRT5 in Acute Myeloid Leukemia$371,250
R01 · FY2022 · CA · contact PI
Strategies to target BCR-ABL1 compound mutants in CML and Ph+ ALL$369,889
R01 · FY2022 · CA · contact PI
Targeting the Metabolic Regulator SIRT5 in Acute Myeloid Leukemia$369,889
R01 · FY2022 · CA · contact PI
A Bioluminescent Assay for Direct Measurement of Sirtuin Activity in Cancer Cells$296,084
R21 · FY2022 · CA · contact PI
Strategies to target BCR-ABL1 compound mutants in CML and Ph+ ALL$348,844
R01 · FY2021 · CA · contact PI
Targeting the Metabolic Regulator SIRT5 in Acute Myeloid Leukemia$324,666
R01 · FY2021 · CA · contact PI
A Bioluminescent Assay for Direct Measurement of Sirtuin Activity in Cancer Cells$309,510
R21 · FY2021 · CA · contact PI
Targeting the Metabolic Regulator SIRT5 in Acute Myeloid Leukemia$24,178
R01 · FY2021 · CA · contact PI
Targeting the Metabolic Regulator SIRT5 in Acute Myeloid Leukemia$348,844
R01 · FY2020 · CA · contact PI
Mechanisms of resistance to ponatinib therapy in chronic myeloid leukemia$483,771
R01 · FY2018 · CA
Mechanisms of resistance to ponatinib therapy in chronic myeloid leukemia$518,975
R01 · FY2017 · CA
SIRT5 as a Therapeutic Target in Acute Myeloid Leukemia$164,620
R21 · FY2017 · CA · contact PI
Mechanisms of resistance to ponatinib therapy in chronic myeloid leukemia$555,104
R01 · FY2016 · CA
SIRT5 as a Therapeutic Target in Acute Myeloid Leukemia$196,402
R21 · FY2016 · CA · contact PI
Mechanisms of resistance to ponatinib therapy in chronic myeloid leukemia$515,946
R01 · FY2015 · CA
Mechanisms of resistance to ponatinib therapy in chronic myeloid leukemia$504,278
R01 · FY2014 · CA
Mechanisms of Chronic Myeloid Leukemia Progenitor Cell Survival$285,055
P01 · FY2014 · CA · contact PI
Mechanisms of Chronic Myeloid Leukemia Progenitor Cell Survival$386,015
P01 · FY2013 · CA · contact PI
Mechanisms of Chronic Myeloid Leukemia Progenitor Cell Survival$296,147
P01 · FY2012 · CA · contact PI
Mechanisms of Chronic Myeloid Leukemia Progenitor Cell Survival$290,164
P01 · FY2011 · CA · contact PI
Mechanisms of Chronic Myeloid Leukemia Progenitor Cell Survival$299,139
P01 · FY2010 · CA · contact PI
IVIS Spectrum Biophotonics Instrument$360,472
S10 · FY2009 · RR · contact PI
Biology of Imatinib-Resistant Mutants of BCR-ABL$132,917
R01 · FY2009 · HL · contact PI
Biology of Imatinib-Resistant Mutants of BCR-ABL$325,345
R01 · FY2008 · HL · contact PI
Biology of Imatinib-Resistant Mutants of BCR-ABL$325,345
R01 · FY2007 · HL · contact PI
Biology of Imatinib-Resistant Mutants of BCR-ABL$335,062
R01 · FY2006 · HL · contact PI
Biology of Imatinib-Resistant Mutants of BCR-ABL$343,125
R01 · FY2005 · HL